The backers were Juvenescence, Ltd. and Longevity Vision Fund.
This financing will enable the company’s lead program in liver regeneration to transition into clinical development, beginning with a Phase 2a clinical trial for patients with end stage liver disease in 2020.
Led by Michael Hufford, PhD, Co-Founder and CEO, LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient’s lymph nodes to be used as bioreactors to regrow functioning ectopic organs. The company’s lead allogeneic cell therapy program is focused on liver regeneration for patients with end stage liver disease.
Its drug development pipeline includes thymus, pancreas, and kidney regeneration.
FinSMEs
21/10/2019